Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | FURIN | P09958 | 9/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | Q9HBH1 | 1/20 | 0.36 | |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17312903 | 1.00 | HTR2A (0.40) | HTR2AFURINFOLH1SSTR3PDF | |
| SCHEMBL25976125 | 0.93 | HTR2A (0.39) | HTR2AFURINFOLH1SSTR3PDF | |
| SCHEMBL17490581 | 0.92 | HTR2A (0.39) | HTR2AFURINFOLH1SSTR3PDF | |
| SCHEMBL23498015 | 0.92 | HTR2A (0.39) | HTR2AFURINFOLH1SSTR3PDF | |
| SCHEMBL23498013 | 0.92 | HTR2A (0.39) | HTR2AFURINFOLH1SSTR3PDF | |
| SCHEMBL25247251 | 0.91 | HTR2A (0.43) | HTR2AFURINSSTR3PDFALDH1A1 | |
| SCHEMBL30479875 | 0.91 | HTR2A (0.43) | HTR2AFURINSSTR3PDFALDH1A1 | |
| SCHEMBL22691442 | 0.90 | FURIN (0.39) | HTR2AFURINFOLH1SSTR3PDF | |
| SCHEMBL19731615 | 0.90 | FURIN (0.39) | HTR2AFURINFOLH1SSTR3PDF | |
| SCHEMBL29678088 | 0.89 | HTR2A (0.44) | HTR2AFURINSSTR3PDFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | HTR2A 4236/4885FURIN 2087/4885FOLH1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.